HTX

HEALTHLINX LIMITED - Announcements

0.00%

0.1¢

Currently unlisted.

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

BEZ +ACE ARJ AXM AYN AZG WZR BGD BHG BIC BUE CCU CFY CMV CPS CWH CYO EIM ELR CO1 KPO FGE GNV HTX IDP IFS IPA IUL LDM MAC MAN MCO MMZ MTD ACF NXS CR3 PAW PLA PSH JGH RIG SAO SAV SFN SHD SOF STI OBM UXA LGR VIP RIL XXL AZL	Suspension from Official Quotation - Annual Listing Fee	PRICE SENSITIVE	25/08/14	35.64KB	Share
HTX	Market Update and Capital Raising	PRICE SENSITIVE	13/06/14	80.35KB	Share
HTX	Suspension from Official Quotation	PRICE SENSITIVE	30/04/13	204.2KB	Share
HTX	Mutual Termination of La Jolla Cove Investors Inc Facility	PRICE SENSITIVE	18/03/13	86.09KB	Share
HTX	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/13	737.55KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/13	190.95KB	Share
HTX	HOA with Mane Cancer Diagnostic Expires	PRICE SENSITIVE	31/12/12	100.68KB	Share
HTX	Chairman's Address to Shareholders	PRICE SENSITIVE	28/11/12	150.51KB	Share
HTX	Primary objective achieved in second OvPlex study	PRICE SENSITIVE	02/11/12	207.15KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/12	148KB	Share
HTX	US Patent Granted to HealthLinx for AGR2 Biomarker	PRICE SENSITIVE	03/09/12	28.19KB	Share
HTX	Appendix 4E and Annual Report 2012	PRICE SENSITIVE	31/08/12	2.12MB	Share
HTX	Sale of IP provides Presence in US markets for assets	PRICE SENSITIVE	03/08/12	30.94KB	Share
HTX	Trading Halt	PRICE SENSITIVE	03/08/12	102KB	Share
HTX	Appendix 4C and Commentary	PRICE SENSITIVE	26/07/12	47.07KB	Share
HTX	OvPlex patent granted in Singapore	PRICE SENSITIVE	06/07/12	25.21KB	Share
HTX	Positive Findings in South Korean Study for OvPlex	PRICE SENSITIVE	27/06/12	32.95KB	Share
HTX	OvPlex distribution expands into India	PRICE SENSITIVE	15/05/12	34.6KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	19/04/12	50.4KB	Share
HTX	New OvPlex Publication and New Prospective Trial	PRICE SENSITIVE	29/03/12	32.78KB	Share
HTX	Pivotal KFDA Study for OvPlex Ready to Commence	PRICE SENSITIVE	20/03/12	32.98KB	Share
HTX	Appendix 4D and half year financial statements December 2011	PRICE SENSITIVE	28/02/12	475.76KB	Share
HTX	Novel biomarker that predicts clinical outcome validated	PRICE SENSITIVE	15/02/12	50.09KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	25/01/12	43.71KB	Share
HTX	Recruitment for OvPlex second trial to be finalised early	PRICE SENSITIVE	16/12/11	36.65KB	Share
HTX	Convertible Note with La Jolla Cove Investors Inc for $9m	PRICE SENSITIVE	08/12/11	32.28KB	Share
HTX	HealthLinx Intellectual Property portfolio strengthened	PRICE SENSITIVE	01/12/11	32.65KB	Share
HTX	Binding HOA with Oryzon Genomics to distribute Ovplex	PRICE SENSITIVE	22/11/11	32.82KB	Share
HTX	HealthLinx CEO to resign as of 30th June 2012	PRICE SENSITIVE	16/11/11	25.66KB	Share
HTX	Prostate collaboration to continue with Garvan Institute	PRICE SENSITIVE	10/11/11	31.49KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/11	49.86KB	Share
HTX	OvPlex patent granted in Hong Kong	PRICE SENSITIVE	26/10/11	64.51KB	Share
HTX	OvPlex patent granted in Hong Kong	PRICE SENSITIVE	26/10/11	242.21KB	Share
HTX	OvPlex trademark granted in China	PRICE SENSITIVE	11/10/11	242.21KB	Share
HTX	Second OvPlex trial reports increased diagnostic efficiency	PRICE SENSITIVE	11/10/11	35.83KB	Share
HTX	INEX to expand OvPlex distribution to Malaysia	PRICE SENSITIVE	07/10/11	31.23KB	Share
HTX	Shareholder Update	PRICE SENSITIVE	27/09/11	29.22KB	Share
HTX	Sigma Aldrich sign license agreement for IgY technology	PRICE SENSITIVE	21/09/11	25.2KB	Share
HTX	China partner appointed for OvPlex diagnostic study	PRICE SENSITIVE	09/09/11	31.2KB	Share
HTX	Appendix 4E and Annual Report	PRICE SENSITIVE	31/08/11	2.32MB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	28/07/11	88.78KB	Share
HTX	HealthLinx secures additional equity funding	PRICE SENSITIVE	30/06/11	33.02KB	Share
HTX	HealthLinx Limited Share Purchase Plan	PRICE SENSITIVE	15/06/11	32.81KB	Share
HTX	Sales of OvPlex in Singapore exceed budget	PRICE SENSITIVE	14/06/11	32.04KB	Share
HTX	Objection to HealthLinx Patent Dismissed	PRICE SENSITIVE	08/06/11	31.44KB	Share
HTX	OvPlex patent granted for Australia	PRICE SENSITIVE	03/06/11	31.85KB	Share
HTX	Collaboration with Garvan Institute on prostate cancer	PRICE SENSITIVE	17/05/11	30.26KB	Share
HTX	AGR2 Patent granted in Europe	PRICE SENSITIVE	10/05/11	28.4KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/11	103.8KB	Share
HTX	Larger OvPlex study confirms 93% diagnostic efficiency	PRICE SENSITIVE	08/03/11	32.22KB	Share
HTX	Appendix 4d and half year Dec10 accounts	PRICE SENSITIVE	28/02/11	256.98KB	Share
HTX	Key OvPlex patent granted	PRICE SENSITIVE	24/02/11	30.13KB	Share
HTX	Ovarian cancer diagnostic study delivers exceptional results	PRICE SENSITIVE	15/02/11	36.11KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/11	90.55KB	Share
HTX	Part 1 of second study confirms superior efficacy of OvPlex	PRICE SENSITIVE	15/12/10	37.89KB	Share
HTX	HealthLinx signs commercial distribution deal in South Korea	PRICE SENSITIVE	02/12/10	36.71KB	Share
HTX	Excellent early results in large OvPlex ovarian cancer study	PRICE SENSITIVE	12/11/10	35.09KB	Share
HTX	Appendix 4C - quarterly with commentary	PRICE SENSITIVE	28/10/10	101.56KB	Share
HTX	Shareholder Update	PRICE SENSITIVE	01/10/10	30.13KB	Share
HTX	Agreement executed with Millipore for AGR2 research	PRICE SENSITIVE	29/09/10	31.66KB	Share
HTX	Expansion of UK Collaborators for International OvPlex Study	PRICE SENSITIVE	09/09/10	31.07KB	Share
HTX	OvPlex ovarian cancer diagnostic licensed for Israel market	PRICE SENSITIVE	07/09/10	38.11KB	Share
HTX	South Korea OvPlex Study Commences for KFDA Approvals	PRICE SENSITIVE	01/09/10	98.25KB	Share
HTX	App 4E and Annual Report 2010	PRICE SENSITIVE	24/08/10	1.01MB	Share
HTX	Appendix 4C and commentary	PRICE SENSITIVE	22/07/10	97.9KB	Share
HTX	HealthLinx progress on prostate cancer diagnostic	PRICE SENSITIVE	22/06/10	57.33KB	Share
HTX	Ethics approval obtained in South Korea for OvPlex study	PRICE SENSITIVE	21/06/10	36.11KB	Share
HTX	Healthscope to distribute OvPlex ovarian cancer test	PRICE SENSITIVE	15/06/10	32.39KB	Share
HTX	Major International Study Begins on OvPlex test	PRICE SENSITIVE	15/06/10	32.92KB	Share
HTX	Stonebridge Securities undertake private placement	PRICE SENSITIVE	01/06/10	31.6KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/10	70.46KB	Share
HTX	OvPlex to be launched in Singapore in July	PRICE SENSITIVE	29/04/10	33.5KB	Share
HTX	OvPlex sales launch in UK on 25 February 2010	PRICE SENSITIVE	24/02/10	41.63KB	Share
HTX	Appendix 4D and Half Year Accounts to December 2009	PRICE SENSITIVE	18/02/10	454.39KB	Share
HTX	Samples secured for commencement of major OvPlex study	PRICE SENSITIVE	17/02/10	32.37KB	Share
HTX	OvPlex diagnostic clinical trial receives UK ethics approval	PRICE SENSITIVE	11/02/10	35.75KB	Share
HTX	HealthLinx expands collaboration with Liverpool University	PRICE SENSITIVE	22/01/10	32.56KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	21/01/10	98.05KB	Share
HTX	Shareholder update	PRICE SENSITIVE	12/01/10	33.33KB	Share
HTX	Spire Healthcare agrees terms to process and market OvPlex	PRICE SENSITIVE	02/12/09	34.89KB	Share
HTX	StoneBridge Securities undertakes private placement of $1.1m	PRICE SENSITIVE	30/11/09	33.49KB	Share
HTX	Trading Halt	PRICE SENSITIVE	30/11/09	45.9KB	Share
HTX	Mater Hospital ethics approval for HealthLinx OvPlex study	PRICE SENSITIVE	23/11/09	33.87KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	29/10/09	71.22KB	Share
HTX	Healthlinx wins $750k Victorian government grant	PRICE SENSITIVE	29/10/09	33.4KB	Share
HTX	Collaborators confirmed for next generation OvPlex study	PRICE SENSITIVE	23/10/09	36.06KB	Share
HTX	$7.2m funding from New York based institutional investor	PRICE SENSITIVE	05/10/09	37.38KB	Share
HTX	Trading Halt	PRICE SENSITIVE	01/10/09	60.52KB	Share
HTX	Mater Health Services partnered in ovarian cancer study	PRICE SENSITIVE	11/09/09	34.93KB	Share
HTX	Appendix 4E	PRICE SENSITIVE	27/08/09	1.05MB	Share
HTX	OvPlex outperforms CA125 by more than 60%	PRICE SENSITIVE	04/08/09	36.84KB	Share
HTX	CE approval for OvPlex ovarian cancer diagnostic test	PRICE SENSITIVE	30/07/09	34.89KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/09	547.93KB	Share
HTX	HealthLinx secures collaborators for major Ovplex study	PRICE SENSITIVE	21/05/09	33.42KB	Share
HTX	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/09	69.84KB	Share
HTX	HealthLinx announces new $3m funding facility	PRICE SENSITIVE	25/03/09	35.57KB	Share
HTX	Appendix 4D and Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/09	813.38KB	Share
HTX	OvPlex diagnostic distribution for Singapore and SE Asia	PRICE SENSITIVE	25/02/09	36.19KB	Share
HTX	HTX Dairy Australia study finds weight reduction compound	PRICE SENSITIVE	23/02/09	37.48KB	Share
HTX	UK distributor to sell OvPlex in UK and Ireland	PRICE SENSITIVE	11/02/09	33.45KB	Share

BEZ +ACE ARJ AXM AYN AZG WZR BGD BHG BIC BUE CCU CFY CMV CPS CWH CYO EIM ELR CO1 KPO FGE GNV HTX IDP IFS IPA IUL LDM MAC MAN MCO MMZ MTD ACF NXS CR3 PAW PLA PSH JGH RIG SAO SAV SFN SHD SOF STI OBM UXA LGR VIP RIL XXL AZL Suspension from Official Quotation - Annual Listing Fee
25/08/14	PRICE SENSITIVE	35.64KB	Share
HTX Market Update and Capital Raising
13/06/14	PRICE SENSITIVE	80.35KB	Share
HTXSuspension from Official Quotation
30/04/13	PRICE SENSITIVE	204.2KB	Share
HTXMutual Termination of La Jolla Cove Investors Inc Facility
18/03/13	PRICE SENSITIVE	86.09KB	Share
HTXHalf Yearly Report and Accounts
28/02/13	PRICE SENSITIVE	737.55KB	Share
HTXAppendix 4C - quarterly
31/01/13	PRICE SENSITIVE	190.95KB	Share
HTXHOA with Mane Cancer Diagnostic Expires
31/12/12	PRICE SENSITIVE	100.68KB	Share
HTXChairman's Address to Shareholders
28/11/12	PRICE SENSITIVE	150.51KB	Share
HTXPrimary objective achieved in second OvPlex study
02/11/12	PRICE SENSITIVE	207.15KB	Share
HTXAppendix 4C - quarterly
31/10/12	PRICE SENSITIVE	148KB	Share
HTXUS Patent Granted to HealthLinx for AGR2 Biomarker
03/09/12	PRICE SENSITIVE	28.19KB	Share
HTXAppendix 4E and Annual Report 2012
31/08/12	PRICE SENSITIVE	2.12MB	Share
HTXSale of IP provides Presence in US markets for assets
03/08/12	PRICE SENSITIVE	30.94KB	Share
HTXTrading Halt
03/08/12	PRICE SENSITIVE	102KB	Share
HTXAppendix 4C and Commentary
26/07/12	PRICE SENSITIVE	47.07KB	Share
HTXOvPlex patent granted in Singapore
06/07/12	PRICE SENSITIVE	25.21KB	Share
HTXPositive Findings in South Korean Study for OvPlex
27/06/12	PRICE SENSITIVE	32.95KB	Share
HTXOvPlex distribution expands into India
15/05/12	PRICE SENSITIVE	34.6KB	Share
HTXAppendix 4C - quarterly
19/04/12	PRICE SENSITIVE	50.4KB	Share
HTXNew OvPlex Publication and New Prospective Trial
29/03/12	PRICE SENSITIVE	32.78KB	Share
HTXPivotal KFDA Study for OvPlex Ready to Commence
20/03/12	PRICE SENSITIVE	32.98KB	Share
HTXAppendix 4D and half year financial statements December 2011
28/02/12	PRICE SENSITIVE	475.76KB	Share
HTXNovel biomarker that predicts clinical outcome validated
15/02/12	PRICE SENSITIVE	50.09KB	Share
HTXAppendix 4C - quarterly
25/01/12	PRICE SENSITIVE	43.71KB	Share
HTXRecruitment for OvPlex second trial to be finalised early
16/12/11	PRICE SENSITIVE	36.65KB	Share
HTXConvertible Note with La Jolla Cove Investors Inc for $9m
08/12/11	PRICE SENSITIVE	32.28KB	Share
HTXHealthLinx Intellectual Property portfolio strengthened
01/12/11	PRICE SENSITIVE	32.65KB	Share
HTXBinding HOA with Oryzon Genomics to distribute Ovplex
22/11/11	PRICE SENSITIVE	32.82KB	Share
HTXHealthLinx CEO to resign as of 30th June 2012
16/11/11	PRICE SENSITIVE	25.66KB	Share
HTXProstate collaboration to continue with Garvan Institute
10/11/11	PRICE SENSITIVE	31.49KB	Share
HTXAppendix 4C - quarterly
28/10/11	PRICE SENSITIVE	49.86KB	Share
HTXOvPlex patent granted in Hong Kong
26/10/11	PRICE SENSITIVE	64.51KB	Share
HTXOvPlex patent granted in Hong Kong
26/10/11	PRICE SENSITIVE	242.21KB	Share
HTXOvPlex trademark granted in China
11/10/11	PRICE SENSITIVE	242.21KB	Share
HTXSecond OvPlex trial reports increased diagnostic efficiency
11/10/11	PRICE SENSITIVE	35.83KB	Share
HTXINEX to expand OvPlex distribution to Malaysia
07/10/11	PRICE SENSITIVE	31.23KB	Share
HTXShareholder Update
27/09/11	PRICE SENSITIVE	29.22KB	Share
HTXSigma Aldrich sign license agreement for IgY technology
21/09/11	PRICE SENSITIVE	25.2KB	Share
HTXChina partner appointed for OvPlex diagnostic study
09/09/11	PRICE SENSITIVE	31.2KB	Share
HTXAppendix 4E and Annual Report
31/08/11	PRICE SENSITIVE	2.32MB	Share
HTXAppendix 4C - quarterly
28/07/11	PRICE SENSITIVE	88.78KB	Share
HTXHealthLinx secures additional equity funding
30/06/11	PRICE SENSITIVE	33.02KB	Share
HTXHealthLinx Limited Share Purchase Plan
15/06/11	PRICE SENSITIVE	32.81KB	Share
HTXSales of OvPlex in Singapore exceed budget
14/06/11	PRICE SENSITIVE	32.04KB	Share
HTXObjection to HealthLinx Patent Dismissed
08/06/11	PRICE SENSITIVE	31.44KB	Share
HTXOvPlex patent granted for Australia
03/06/11	PRICE SENSITIVE	31.85KB	Share
HTXCollaboration with Garvan Institute on prostate cancer
17/05/11	PRICE SENSITIVE	30.26KB	Share
HTXAGR2 Patent granted in Europe
10/05/11	PRICE SENSITIVE	28.4KB	Share
HTXAppendix 4C - quarterly
29/04/11	PRICE SENSITIVE	103.8KB	Share
HTXLarger OvPlex study confirms 93% diagnostic efficiency
08/03/11	PRICE SENSITIVE	32.22KB	Share
HTXAppendix 4d and half year Dec10 accounts
28/02/11	PRICE SENSITIVE	256.98KB	Share
HTXKey OvPlex patent granted
24/02/11	PRICE SENSITIVE	30.13KB	Share
HTXOvarian cancer diagnostic study delivers exceptional results
15/02/11	PRICE SENSITIVE	36.11KB	Share
HTXAppendix 4C - quarterly
28/01/11	PRICE SENSITIVE	90.55KB	Share
HTXPart 1 of second study confirms superior efficacy of OvPlex
15/12/10	PRICE SENSITIVE	37.89KB	Share
HTXHealthLinx signs commercial distribution deal in South Korea
02/12/10	PRICE SENSITIVE	36.71KB	Share
HTXExcellent early results in large OvPlex ovarian cancer study
12/11/10	PRICE SENSITIVE	35.09KB	Share
HTXAppendix 4C - quarterly with commentary
28/10/10	PRICE SENSITIVE	101.56KB	Share
HTXShareholder Update
01/10/10	PRICE SENSITIVE	30.13KB	Share
HTXAgreement executed with Millipore for AGR2 research
29/09/10	PRICE SENSITIVE	31.66KB	Share
HTXExpansion of UK Collaborators for International OvPlex Study
09/09/10	PRICE SENSITIVE	31.07KB	Share
HTXOvPlex ovarian cancer diagnostic licensed for Israel market
07/09/10	PRICE SENSITIVE	38.11KB	Share
HTXSouth Korea OvPlex Study Commences for KFDA Approvals
01/09/10	PRICE SENSITIVE	98.25KB	Share
HTXApp 4E and Annual Report 2010
24/08/10	PRICE SENSITIVE	1.01MB	Share
HTXAppendix 4C and commentary
22/07/10	PRICE SENSITIVE	97.9KB	Share
HTXHealthLinx progress on prostate cancer diagnostic
22/06/10	PRICE SENSITIVE	57.33KB	Share
HTXEthics approval obtained in South Korea for OvPlex study
21/06/10	PRICE SENSITIVE	36.11KB	Share
HTXHealthscope to distribute OvPlex ovarian cancer test
15/06/10	PRICE SENSITIVE	32.39KB	Share
HTXMajor International Study Begins on OvPlex test
15/06/10	PRICE SENSITIVE	32.92KB	Share
HTXStonebridge Securities undertake private placement
01/06/10	PRICE SENSITIVE	31.6KB	Share
HTXAppendix 4C - quarterly
29/04/10	PRICE SENSITIVE	70.46KB	Share
HTXOvPlex to be launched in Singapore in July
29/04/10	PRICE SENSITIVE	33.5KB	Share
HTXOvPlex sales launch in UK on 25 February 2010
24/02/10	PRICE SENSITIVE	41.63KB	Share
HTXAppendix 4D and Half Year Accounts to December 2009
18/02/10	PRICE SENSITIVE	454.39KB	Share
HTXSamples secured for commencement of major OvPlex study
17/02/10	PRICE SENSITIVE	32.37KB	Share
HTXOvPlex diagnostic clinical trial receives UK ethics approval
11/02/10	PRICE SENSITIVE	35.75KB	Share
HTXHealthLinx expands collaboration with Liverpool University
22/01/10	PRICE SENSITIVE	32.56KB	Share
HTXAppendix 4C - quarterly
21/01/10	PRICE SENSITIVE	98.05KB	Share
HTXShareholder update
12/01/10	PRICE SENSITIVE	33.33KB	Share
HTXSpire Healthcare agrees terms to process and market OvPlex
02/12/09	PRICE SENSITIVE	34.89KB	Share
HTXStoneBridge Securities undertakes private placement of $1.1m
30/11/09	PRICE SENSITIVE	33.49KB	Share
HTXTrading Halt
30/11/09	PRICE SENSITIVE	45.9KB	Share
HTXMater Hospital ethics approval for HealthLinx OvPlex study
23/11/09	PRICE SENSITIVE	33.87KB	Share
HTXAppendix 4C - quarterly
29/10/09	PRICE SENSITIVE	71.22KB	Share
HTXHealthlinx wins $750k Victorian government grant
29/10/09	PRICE SENSITIVE	33.4KB	Share
HTXCollaborators confirmed for next generation OvPlex study
23/10/09	PRICE SENSITIVE	36.06KB	Share
HTX$7.2m funding from New York based institutional investor
05/10/09	PRICE SENSITIVE	37.38KB	Share
HTXTrading Halt
01/10/09	PRICE SENSITIVE	60.52KB	Share
HTXMater Health Services partnered in ovarian cancer study
11/09/09	PRICE SENSITIVE	34.93KB	Share
HTXAppendix 4E
27/08/09	PRICE SENSITIVE	1.05MB	Share
HTXOvPlex outperforms CA125 by more than 60%
04/08/09	PRICE SENSITIVE	36.84KB	Share
HTXCE approval for OvPlex ovarian cancer diagnostic test
30/07/09	PRICE SENSITIVE	34.89KB	Share
HTXAppendix 4C - quarterly
27/07/09	PRICE SENSITIVE	547.93KB	Share
HTXHealthLinx secures collaborators for major Ovplex study
21/05/09	PRICE SENSITIVE	33.42KB	Share
HTXAppendix 4C - quarterly
28/04/09	PRICE SENSITIVE	69.84KB	Share
HTXHealthLinx announces new $3m funding facility
25/03/09	PRICE SENSITIVE	35.57KB	Share
HTXAppendix 4D and Half Yearly Report and Accounts
25/02/09	PRICE SENSITIVE	813.38KB	Share
HTXOvPlex diagnostic distribution for Singapore and SE Asia
25/02/09	PRICE SENSITIVE	36.19KB	Share
HTXHTX Dairy Australia study finds weight reduction compound
23/02/09	PRICE SENSITIVE	37.48KB	Share
HTXUK distributor to sell OvPlex in UK and Ireland
11/02/09	PRICE SENSITIVE	33.45KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

HEALTHLINX LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Top Stories

Corporate Spotlight
Not Yet Available